Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease ; volume:13 ; number:1 ; day:4 ; month:2 ; year:2023 ; pages:1-20 ; date:12.2023
Scientific reports ; 13, Heft 1 (4.2.2023), 1-20, 12.2023
- Creator
-
Fertan, Emre
Gendron, William H.
Wong, Aimée A.
Hanson, Gabrielle M.
Brown, Richard E.
Weaver, Ian C. G.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-29248-x
- URN
-
urn:nbn:de:101:1-2023040909034452072856
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fertan, Emre
- Gendron, William H.
- Wong, Aimée A.
- Hanson, Gabrielle M.
- Brown, Richard E.
- Weaver, Ian C. G.
- SpringerLink (Online service)
Other Objects (12)
Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology
Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease
Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer’s Disease
Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease
Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics
Quantitative characterization of amyloid-beta interaction with artificial compounds designed for Alzheimer´s disease therapy
Exploring non-canonical targets in Alzheimer’s disease: a departure from the norm
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology
Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease
Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer’s Disease
Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease
Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics
Quantitative characterization of amyloid-beta interaction with artificial compounds designed for Alzheimer´s disease therapy
Exploring non-canonical targets in Alzheimer’s disease: a departure from the norm
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology
Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease
Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer’s Disease
Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease
Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics
Quantitative characterization of amyloid-beta interaction with artificial compounds designed for Alzheimer´s disease therapy
Exploring non-canonical targets in Alzheimer’s disease: a departure from the norm